Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Andy Chen
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters; questions recorded in 4).
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 4with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 2 companies
INCYIncyte3 questions · 3 reporting periods · 0 of 3 challenging
Calendar 2026 Q2
how well is the Jakafi XR conversion tracking along your internal metrics so far?
Show response
Issa confirmed reimbursement has already begun, tied the exit-rate demand share to the full-year sales range, and reiterated the 50 to 70% coverage goal.
Calendar 2025 Q4
any preliminary conversations with payers on formulary access? Or early signs that give you confidence on the eventual launch here
Show response
Bill outlined XR formulary strategy: medical rationale (adherence gain 15-25%), price that makes sense for all stakeholders, targeting 80-100% coverage though not top tier. Expects 10-30% conversion rate with most of 2026 focused on formulary access.
Calendar 2024 Q4
can you talk about specific protocol differences between your trial and other trials, especially from IL-17 antibodies?
Show response
Herve noted careful site selection and training to replicate Phase 2 methodology. Higher proportion of more advanced disease patients to reduce placebo effect. Both doses possible for label if positive.
INSMInsmed Incorporated1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q1
can you please provide some timing expectation around this diagnosis expansion? Or maybe, in other words, can you maybe speak more regarding the appropriate industry analogs
Show response
Management expects initial results from diagnosis expansion by end of 2026, more robust impact in 2027. Highlighted existing CT scans that were never evaluated for bronchiectasis and the ATS initiative at 7 centers as key catalysts.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| INCY Incyte | 3 | 0%none of 3 questions |
| INSM Insmed Incorporated | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | No questions recorded | — | — |
| 2025 Q2 | No questions recorded | — | — |
| 2025 Q3 | No questions recorded | — | — |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 1 | 0%none of 1 question | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q1No questions recorded
- 2025 Q2No questions recorded
- 2025 Q3No questions recorded
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q21 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Product Launch2
- Demand2
- Competitive Dynamics2
- Pricing1
- Regulation Policy1
- Innovation & R&D1